NAIROBI, November 10, 2023. Sinopharm East Africa welcomed a delegation from China’s Wuhan Institute of Biological Products. During their visit, Chairman Wu Hongjin and General Manager Li Zhen led the Wuhan Institute on tours of the Kenya Pharmacy and Poisons Board (KPPB) and its laboratories, the Kenya Ministry of Health, the Chinese Embassy in Kenya, Victoria Biomedical Research Institute, as well as major hospitals and pharmaceutical markets. This initial exploration provided valuable insights into Kenya's healthcare system and conditions, laying a strategic foundation for the Wuhan Institute's future market entry into Africa.

Chairman Wu Hongjin accompanied the Wuhan Institute of Biological Products delegation in their meeting with the CEO of the KPPB: 

General Manager Li Zhen guided the Wuhan Institute through the KPPB's laboratory facilities: 

Sinopharm East Africa's distribution of Wuhan Institute's influenza vaccine officially commences in Kenya:

Established in 2013 and based in Nairobi, the capital city of Kenya, Sinopharm East Africa is the only Chinese-funded CRO enterprise in Kenya, and home to the country’s sole fully Chinese-backed medical testing laboratory. Partnering with numerous prominent domestic companies, we offer a range of services including clinical research, product registration, academic promotion, and marketing. With our base in Kenya, we serve the broader East African region, maintaining long-standing cooperative relationships with government bodies such as the Ministry of Health and the KPPB, as well as the World Health Organization. Our comprehensive platform supports all aspects of our operations.